22.07.2013 Views

Research and treatment timeline: 30+ years of ms milestones | 4

Research and treatment timeline: 30+ years of ms milestones | 4

Research and treatment timeline: 30+ years of ms milestones | 4

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>ms</strong> canada Fall/Winter 2012 2<br />

am <strong>of</strong>ten reminded,<br />

I during conversations<br />

with people living with<br />

multiple sclerosis,<br />

that hope for an end<br />

Yves savoie<br />

to MS can mean<br />

very different things<br />

to different people. Whether it’s hope for a<br />

cure or hope for more effective symptom<br />

management, we are hopeful that advances<br />

in research will one day <strong>of</strong>fer a means to an<br />

end to MS. This issue <strong>of</strong> MS Canada focuses<br />

on research, past <strong>and</strong> present. Through<br />

increasing our knowledge about multiple<br />

sclerosis we are hopeful that a future free <strong>of</strong><br />

this disease can exist.<br />

We welcome the federal government’s<br />

announcement that the Phase I/II clinical trial<br />

for chronic cerebrospinal venous insufficiency<br />

(CCSVI) has received the necessary medical<br />

<strong>and</strong> ethical approvals required to proceed.<br />

The national MS interventional clinical trial<br />

is a collaborative initiative between the<br />

Government <strong>of</strong> Canada, provinces where there<br />

are trial sites <strong>and</strong> the MS Society. We are<br />

hopeful that the research <strong>of</strong> Dr. Traboulsee<br />

<strong>and</strong> his collaborators will provide significant<br />

insights to those living with MS <strong>and</strong> provide<br />

answers on questions about CCSVI <strong>and</strong> MS.<br />

My sincerest thanks to those who provided<br />

feedback on the Renewal Initiative, a 12-month<br />

process <strong>of</strong> engagement that sought ways for<br />

Ms Canada, Fall/Winter 2012<br />

Published by the Multiple Sclerosis Society <strong>of</strong> Canada<br />

175 Bloor St. E., Suite 700, Toronto ON M4W 3R8<br />

Tel: (416) 922-6065 • Fax: (416) 922-7538<br />

Toll free: 1-866-922-6065 • Website: <strong>ms</strong>society.ca/<strong>ms</strong>canada<br />

Charitable Registration no. 10774 6174 RR0001<br />

Our Mission: To be a leader in finding a cure for multiple sclerosis<br />

<strong>and</strong> enabling people affected by MS to enhance their quality <strong>of</strong> life.<br />

President <strong>and</strong> chief executive <strong>of</strong>ficer: Yves Savoie<br />

Editor-in-chief: Tiffany Regaudie<br />

Managing editor: Krysta Celestine<br />

ISSN 0315-1131<br />

Canadian Publications Mail Product<br />

Sales Agreement No. 40063383<br />

Message from yves<br />

the MS Society to be more effective <strong>and</strong><br />

efficient in delivering upon its mission. To those<br />

who provided input during this process, please<br />

know that you have played a significant role<br />

in helping to ensure that we will continue to<br />

best serve those affected by MS. For up to date<br />

information on the Renewal Initiative please<br />

visit <strong>ms</strong>society.ca/renewal<br />

I am also pleased to announce the<br />

appointment <strong>of</strong> Owen Charters to the<br />

position <strong>of</strong> chief development <strong>of</strong>ficer (CDO)<br />

effective January 14, 2013. Owen has played<br />

significant leadership roles spanning from<br />

hospital foundations to member-based,<br />

multi-level national organizations. Owen<br />

served CanadaHelps as president <strong>and</strong> chief<br />

executive <strong>of</strong>ficer since 2007 <strong>and</strong> is currently<br />

adjunct faculty at the Schulich School <strong>of</strong><br />

Business at York University. Owen will provide<br />

strategic vision <strong>and</strong> dynamic leadership as<br />

the architect <strong>of</strong> the MS Society’s development<br />

<strong>and</strong> marketing progra<strong>ms</strong>.<br />

A note <strong>of</strong> recognition <strong>and</strong> gratitude is also<br />

extended to Genzyme, a San<strong>of</strong>i Company,<br />

for their support <strong>of</strong> this edition <strong>of</strong> MS Canada<br />

through an unrestricted educational grant. I<br />

have heard from people living with MS that<br />

research brings them hope. I share in this<br />

sentiment <strong>and</strong> hope that the future will also<br />

bring answers <strong>and</strong> a cure. ■<br />

Yves Savoie<br />

Attention! We would like to keep in touch<br />

via email. If you would like to receive future<br />

issues <strong>of</strong> MS Canada electronically instead<br />

<strong>of</strong> a printed version, please send your full<br />

name, current address <strong>and</strong> email address to<br />

<strong>ms</strong>canada@<strong>ms</strong>society.ca<br />

ON THE COVER: Dr. Jiwon Oh, winner <strong>of</strong><br />

the Decker Family endMS <strong>Research</strong> <strong>and</strong> Training<br />

Network Transitional Career Development Award

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!